Aion Therapeutic Inc. (CSE: AION) announces that further to its press releases of September 13, 2022, September 26, 2022, October 11, 2022 and October 31, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203“).

On August 30, 2022, the Company announced (the “Default Announcement“) that it had not filed its annual financial statements and management discussion and analysis for the year ended April 30, 2022, together with the related certification of filings under National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and Interim Filings (collectively, the “Annual Disclosure Documents“) by the prescribed deadline of August 29, 2022 and the subsequent delay in filing the Company’s interim financial statement and management discussion and analysis for the three-month period ended July 31, 2022 (the “Interim Disclosure Documents“) by the prescribed deadline of September 29, 2022.

About Aion Therapeutic Inc

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.